Open AccessThe Anticipated Next Season of EGFR Inhibitors
Author(s) -
Sequist Lecia V.
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0086
Subject(s) - somatic cell , germline , t790m , medicine , lung cancer , resistance (ecology) , value (mathematics) , cancer , biology , oncology , epidermal growth factor receptor , computer science , genetics , gene , gefitinib , ecology , machine learning
EGFR‐directed therapy in lung cancer is here to stay, with new drugs targeting T790M‐mediated resistance coming quickly and the field continuing to advance. With greater access to sophisticated tools for interrogating both the somatic and germline genome, and with widespread acceptance of the scientific and clinical value of obtaining serial repeated biopsies from patients with oncogene‐addicted tumors, the field is poised to answer more nuanced questions.